MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
Authors
Keywords
Aggressive pituitary adenoma, MGMT, MSH6, TMZ
Journal
Pituitary
Volume 20, Issue 6, Pages 643-653
Publisher
Springer Nature
Online
2017-09-12
DOI
10.1007/s11102-017-0829-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
- (2017) S L Asa et al. ENDOCRINE-RELATED CANCER
- A Structural and Functional Acromegaly Classification
- (2015) Daniel Cuevas-Ramos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification
- (2015) Alexander S. G. Micko et al. JOURNAL OF NEUROSURGERY
- Endoplasmic reticulum protein 29 (ERp29) confers radioresistance through the DNA repair gene, O6-methylguanine DNA-methyltransferase, in breast cancer cells
- (2015) Shaohua Chen et al. Scientific Reports
- Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma
- (2014) Luis Syro et al. Hormones-International Journal of Endocrinology and Metabolism
- Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy
- (2014) Olga Moshkin et al. Hormones-International Journal of Endocrinology and Metabolism
- Acromegaly: An Endocrine Society Clinical Practice Guideline
- (2014) Laurence Katznelson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
- (2013) Jacqueline Trouillas et al. ACTA NEUROPATHOLOGICA
- DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
- (2013) Toshio Hirohata et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
- (2012) Ida Casorelli et al. Anti-Cancer Agents in Medicinal Chemistry
- Clinicopathological Correlations in Pituitary Adenomas
- (2012) Ozgur Mete et al. BRAIN PATHOLOGY
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment
- (2012) Gérald Raverot et al. CLINICAL ENDOCRINOLOGY
- MGMT expression and pituitary tumours: relationship to tumour biology
- (2012) Ann McCormack et al. Pituitary
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
- (2011) Ann I. McCormack et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
- (2011) Shlomo Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas
- (2011) Fateme Salehi et al. JOURNAL OF NEURO-ONCOLOGY
- A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report
- (2011) Mineko Murakami et al. NEUROSURGERY
- Excess mortality for patients with residual disease following resection of pituitary adenomas
- (2011) Michael E. Sughrue et al. Pituitary
- Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature
- (2011) A. K. Annamalai et al. Pituitary
- Treatment of pituitary neoplasms with temozolomide
- (2010) Luis V. Syro et al. CANCER
- MGMT Immunoexpression in Silent Subtype 3 Pituitary Adenomas: Possible Therapeutic Implications
- (2010) Michael E. Fealey et al. ENDOCRINE PATHOLOGY
- Low Immunohistochemical Expression of MGMT in ACTH Secreting Pituitary Tumors of Patients with Nelson Syndrome
- (2010) Fateme Salehi et al. ENDOCRINE PATHOLOGY
- Mortality in Patients with Pituitary Disease
- (2010) Mark Sherlock et al. ENDOCRINE REVIEWS
- MIB-1 labeling index correlated with magnetic resonance imaging detected tumor volume doubling time in pituitary adenoma
- (2010) Chih-Yi Hsu et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients
- (2010) Sophie Brochier et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Atypical pituitary adenomas: incidence, clinical characteristics, and implications
- (2010) Gabriel Zada et al. JOURNAL OF NEUROSURGERY
- Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review
- (2010) Paulo Henrique Pires de Aguiar et al. NEUROLOGICAL RESEARCH
- MGMT immunoexpression in aggressive pituitary adenoma and carcinoma
- (2010) Queenie Lau et al. Pituitary
- O6-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas
- (2009) Georg Widhalm et al. CANCER
- Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma
- (2009) C. K. Augustine et al. CLINICAL CANCER RESEARCH
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease
- (2009) Akira Takeshita et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- P53gene mutation in an atypical corticotroph adenoma with Cushing's disease
- (2008) Sachiko-Tsukamoto Kawashima et al. CLINICAL ENDOCRINOLOGY
- Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
- (2008) Ann I. McCormack et al. CLINICAL ENDOCRINOLOGY
- Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas
- (2008) Roger Gejman et al. HUMAN PATHOLOGY
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
- (2008) B. M. K. Biller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression
- (2008) Georg Widhalm et al. JOURNAL OF NEUROSURGERY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started